Disease‐specific mortality ‐ not reported · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in disease‐specific mortality compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Intervention not reported
Variceal bleeding 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease (grade 3 or 4 fibrosis)…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ascites 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease (grade 3 or 4 fibrosis)…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
First recurrence · high‐risk melanoma participants
The intervention leads to lower first recurrence (high certainty).
1 finding from 1 review
Intervention not reported
Death · high‐risk melanoma participants
The intervention leads to lower death (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (6 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (6 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention leads to lower sustained (3 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 or 6 months) EDSS increase at 3 years in patients with pre study relapses · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (3 or 6 months) EDSS increase at 3 years in patients with… (high certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one relapse during · patients with secondary progressive multiple sclerosis
The intervention leads to lower number of patients with at least one relapse during (high certainty).
1 finding from 1 review
Intervention not reported
Patients with progression of the disease ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with progression of the disease ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with severe adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with severe adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with any related adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention leads to higher patients with any related adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Mean EDSS change at two years ( · patients with Primary Progressive Multiple Sclerosis
1 finding from 1 review
Intervention not reported
Sustained increase in spasticity ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in sustained increase in spasticity ( (high certainty).
1 finding from 1 review